Albireo
Altor BioScience Corp.
Amnis Corp.
Argos Therapeutics, Inc.
Ascent Therapeutics, Inc.
Biovertis AG
Cerenis Therapeutics
Concert Pharmaceuticals, Inc.
Curacyte AG
CyDex, Inc.
DeveloGen AG
DIREVO Industrial Biotechnology GmbH
elbion AG
Enanta Pharmaceuticals, Inc.
EUSA Pharma
f-star
Genetix Pharmaceuticals, Inc.
invendo medical GmbH
Magen BioSciences, Inc.
Nitec Pharma AG
NOXXON Pharma AG
Precision Therapeutics, Inc.
Probiodrug AG
Proteon Therapeutics, Inc.
Riemser Arzneimittel AG
SelectX Pharmaceuticals, Inc.
Spepharm Holding BV
Talia Technology Ltd.
Transave, Inc.
TransMolecular, Inc.
Vivendy Therapeutics AG
Addex Pharmaceuticals SA
Ardana plc
Ark Therapeutics Ltd.
Biotie Therapies Corp.
BioXell S.p.A
EpiCept Corp
Evotec AG
GPC Biotech AG
MediGene AG
Newron Pharmaceuticals S.p.A
Wilex AGWe build on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and almost 40 IPOs in biotechnology and biopharmaceuticals.
We help entrepreneurs conceptualize and launch technology-based companies with seed and early stage funding, we develop single drug assets with our own set up of industry specialists, and we also provide growth capital to private or public companies in their commercialization phase by financing market introductions, a broadening of their product portfolio, acquisitions or international expansion.
Our portfolio companies have their roots in the world renowned academic institutions of MIT, Harvard Medical School and the Max-Planck Society; public and privately-held biotech companies, especially for consolidation and roll-up concepts; and spin-outs from the international pharmaceutical industry leaders.